PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Updates on PARP Inhibitors From ESGO 2021
Visit https://www.peervoice.com/EZA860 to view the entire programme with slides. After completing “Updates on PARP Inhibitors From ESGO 2021”, participants will be able to: Identify the diverse factors that can influence treatment decision-making in advanced ovarian cancer; Evaluate recent clinical evidence for PARP inhibitors in the management of advanced ovarian cancer; Translate current and emerging evidence into optimal treatment strategies for patients with advanced ovarian cancer